Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10968989 | Vaccine | 2011 | 9 Pages |
Abstract
PspA is one of the most well studied pneumococcal proteins and a promising candidate for a future protein-based anti-pneumococcal vaccine. Nevertheless, its structural and serological variability suggests the inclusion of more than one PspA molecule in order to broaden protection. Since different PspAs exhibit variable levels of cross-reactivity, the selection of the protein combination with the highest coverage potential is an essential step for PspA-based vaccine development. This work investigated the level of cross-reactivity within family 1 PspAs, and established a complement based antibody mediated opsonophagocytic assay for measuring the level of cross-protection. Among a panel of ten family 1 PspA molecules, two of them, one belonging to clade 1 and another from clade 2, induced antibodies capable of enhancing complement deposition and mediating the phagocytic killing by mouse peritoneal macrophages of all pneumococci bearing PspA family 1 strains tested, regardless of their serotype. Therefore, we suggest the inclusion of either one in a PspA-based vaccine, as a representative of family 1. Furthermore, our results suggest that opsonophagocytosis by mouse peritoneal cells can be an efficient means of evaluating the induction of protective immune responses in mice across a large number of strains.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Cibelly Goulart, Michelle Darrieux, Dunia Rodriguez, Fabiana C. Pimenta, Maria Cristina C. Brandileone, Ana Lucia S.S. de Andrade, Luciana C.C. Leite,